Edition:
United Kingdom

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

0.44USD
23 Apr 2018
Change (% chg)

-- (--)
Prev Close
$0.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,272
52-wk High
$3.42
52-wk Low
$0.43

Chart for

About

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition,... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $43.07
Shares Outstanding(Mil.): 20.12
Dividend: --
Yield (%): --

Financials

  PULM.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.37 -- --
ROI: -104.24 1.58 14.38
ROE: -122.80 2.41 16.07

BRIEF-Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook On Pulmonary Disease Pipeline

* PULMATRIX REPORTS 2017 FINANCIAL RESULTS; PROVIDES 2018 OUTLOOK ON PULMONARY DISEASE PIPELINE

13 Mar 2018

BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole

* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE

12 Feb 2018

BRIEF-Pulmatrix posts Q3 net loss of $0.22 per share

* Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials

09 Nov 2017

Earnings vs. Estimates